I'm delighted to extend a warm welcome back to Adam Feuerstein.

Longtime readers may remember his insightful commentary and enterprise reporting on the biotech sector from years past. His coverage of ImClone Systems for TheStreet.com garnered him a nomination for the Online Journalism Awards back in 2002. Adam left us in January 2005 to pursue a career as a research analyst, covering biotech stocks for a New York-based investment firm.

While he put his two-year stint on Wall Street to productive use by bolstering his knowledge of fundamental stock analysis, he missed journalism and has decided to come back to his true calling. He'll now be a regular writer on our site, with an even better understanding of the way Wall Street works -- along with a newfound talent for whizzing through Excel spreadsheets.

Click here for his first column.

We're thrilled to have Adam back in the fold. Please offer him a warm welcome, and as always, let us know what you think.

Let's stay interactive.

Dave Morrow
Editor-in-chief
David Morrow is editor-in-chief of TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, though he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. He appreciates your feedback; click here to send him an email.

If you liked this article you might like

Opinion: Don't Question the Almighty

Opinion: Don't Question the Almighty

What You're Missing on RealMoney

What You're Missing on RealMoney

How RealMoney Can Prevent a Disaster

How RealMoney Can Prevent a Disaster

Profit With RealMoney

Profit With RealMoney

The Bonanza Calls of Biotech Select

The Bonanza Calls of Biotech Select